| toreforant (JNJ-38518168) / J&J |
NCT01450982: A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants |
|
|
| Completed | 1 | 20 | US | JNJ-38518168 / MTX | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Rheumatoid Arthritis | | 10/11 | | |
NCT01442532: A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam |
|
|
| Completed | 1 | 94 | US | JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168 | Janssen Research & Development, LLC | Healthy Male Volunteer | 07/12 | 07/12 | | |
NCT01970020: A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants. |
|
|
| Completed | 1 | 6 | Europe | JNJ-38518168 | Janssen Research & Development, LLC | Healthy | 12/12 | 12/12 | | |
NCT01690286: Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers |
|
|
| Completed | 1 | 33 | US | JNJ-38518168 3 mg, JNJ-38518168 30 mg, JNJ-38518168 10 mg, Ketoconazole 200 mg | Janssen Research & Development, LLC | Healthy | 12/12 | 12/12 | | |
NCT01863784: A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function |
|
|
| Completed | 1 | 28 | US | JNJ-38518168 | Janssen Research & Development, LLC | Hepatic Impairment | 11/13 | 11/13 | | |
